METABOLIC & WEIGHT RESEARCH / COLOPHON
Contact the Editorial Desk
Correspondence on citations, corrections, and research-related inquiries — the things a reference desk is most useful to hear about.
Editorial correspondence
Smart Choice Peptides welcomes correspondence about the research record itself: a citation quoted inaccurately, a newly published trial result, a regulatory status change, or a peer-reviewed study on AOD-9604, tesamorelin, or tirzepatide that should be added to the references page. Corrections that improve the accuracy or currency of this digest are the most useful messages this desk receives.
The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference — a DOI or PubMed identifier wherever possible — so a proposed change can be verified against its source before anything is edited.
Editorial mailbox: editors@smartchoicepeptides.com
What this desk cannot do
A few things sit outside what this desk can do, and saying so plainly beats leaving a note unanswered. It reads and compares literature; it runs no clinical service and sells nothing, so it cannot green-light or steer anyone's use of these compounds, name a dose or schedule for an individual, judge whether a cited trial result maps onto one person's situation, or sell, source, or help locate any compound from any supplier. Tesamorelin and tirzepatide are prescription medicines available only through licensed providers; AOD-9604 is not an approved medicine anywhere. Anyone weighing a real decision should take it to a clinician licensed where they live. Editorial mail is read when time allows, and a reply is not promised.